NCT01713582View on ClinicalTrials.gov

A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)

PHASE1CompletedINTERVENTIONAL

Enrollment

141

Participants

Timeline

Start Date

December 14, 2012

Primary Completion Date

January 20, 2017

Study Completion Date

January 20, 2017

Conditions

Acute Myeloid LeukemiaDiffuse Large B-cell LymphomaAcute Lymphoblastic LeukemiaMultiple Myeloma

Interventions

DRUG

OTX015/Birabresib

OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

All Listed Sponsors

lead

Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT01713582 - A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) | Biotech Hunter | Biotech Hunter